Clinical Trials Browser

Hodgkin Disease, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Therapy for Children With Advanced Stage Neuroblastoma

Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma

Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma

TIL Therapy in cSCC and MCC

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study

DiTuSarc

Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma

Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

SBRT/IL-2

Study of High Dose Interleukin-2 (IL-2) and Stereotactic Body Radiation (SBRT) in Patients With Metastatic Renal Cancer

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma

PragmaTIL

Study of Adoptive Transfer of iNKT Cells Combined With TAE/TACE to Treat Unresectable HCC

Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma

COREVAX-1

RaC-Ad

Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma

Lifileucel With Reduced Dose Fludarabine/Cyclophosphamide Lymphodepletion and Interleukin-2 for the Treatment of Patients With Unresectable or Metastatic Melanoma

Radiation and Combination Immunotherapy for Melanoma

PANCEP-1

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

High Dose IL 2 and Entinostat in RCC

Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma

High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery

METILDA

Cytokine-induced Memory-like NK Cells in Combination With Chemotherapy in Pediatric Patents With Refractory or Relapsed AML

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma

PRaG Regimens Rechallenge for Patients With Resistance to PD1/PD-L1 Inhibitors in Refractory Advanced Solid Tumors.

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

ADC Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of HER-2 Positive Advanced Solid Tumors(PRaG3.0)

High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer

NK Cells as Consolidation Therapy of Acute Myeloid Leukemia in Children/Adolescents

Biochemotherapy With Temozolomide for Metastatic Melanoma

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

High-Dose Interleukin-2 (HDIL-2), Combined With recMAGE-A3 + AS15 ASCI

Study of IL2 in Combination With Zoledronic Acid in Patients With Kidney Cancer

Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Phase II Study of Allo LMI Vaccine With IL-2 for Stable Metastatic Breast Ca

High Dose Interleukin-2 Followed by Intermittent Low Dose Temozolomide in Patients With Melanoma

RENALVax-2

ATTACK-OG

DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC

IL2 for GVHD